Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Cisplatin in HPV+ Solid Tumors
NCT02620839Phase 1Terminated
- Sponsor
- Alessa Therapeutics
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib in solid tumor (7 cohorts), sponsored by Alessa Therapeutics. Primary endpoints: Maximally Tolerated Dose at 21 days and Recommended Phase 2 Dose at 30 days. Started Dec 2016; status: terminated.
02
Drugs
alpelisib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02620839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620839.